Press Releases
InspireMD Reports 132% Increase in CGuard⢠EPS Sales for the First Quarter of 2018
Tel Aviv, Israelâ May 7, 2018 – InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced results for the first quarter ending March 31, 2018. First Quarter 2018 highlights: Achieves revenue of $1.0 million for Q1 2018 versus $569,000 in Q1 2017, an increase… Read More
InspireMD Schedules First Quarter 2018 Earnings Conference Call
Tel Aviv â May 1, 2018 â InspireMD, Inc. (NYSE: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Monday, May 7th at 4:30 p.m. Eastern Time to discuss the companyâs financial results for the first quarter ended March… Read More
InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard⢠EPS and MGuard Prime⢠Products in Vietnam
Tel Aviv, Israelâ April 30, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has received regulatory approval, and has initiated commercialization of its CGuard⢠Embolic Prevention System (EPS) and MGuard Prime⢠in Vietnam. Both of these devices utilize the company’s patented MicroNet⢅ Read More
InspireMDâs CGuard⢠Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, PolandInspireMDâs CGuard⢠Embolic Prevention System to be Featured at ICCA Stroke 2018 in Warsaw, Poland
 Tel Aviv, Israelâ April 19, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that its CGuard⢠Embolic Prevention System will be featured at the ICCA Stroke 2018 conference to be held April 20th-21st at the Institute of Psychiatry and Neurology in Warsaw, Poland…. Read More
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard⢠EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
Tel Aviv, Israelâ April 3, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary unaudited sales results for the first quarter of 2018. Highlights for the fiscal first quarter of 2018 as compared to the fiscal first quarter of 2017(1): ⌠Total company… Read More
InspireMD, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock
Tel Aviv, Israelâ March 28, 2018 â InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock at a price to the public of $1.75 per share. InspireMD expects to receive aggregate… Read More
InspireMD, Inc. Announces Proposed Public Offering of Common Stock
Tel Aviv, Israelâ March 27, 2018 â InspireMD, Inc. (NYSE American: NSPR),  a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. InspireMD also expects to grant the… Read More
InspireMD Receives Regulatory Approval for both CGuard⢠EPS and MGuard Prime⢠in Peru
Tel Aviv, Israelâ March 27, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it has received regulatory approval for the CGuard⢠Embolic Prevention System (EPS) and MGuard Prime⢠in Peru. The approval was granted by Peruâs Ministry of Health. In May of… Read More
InspireMD Announces First Patient Treated with CGuardTM EPS in India
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuardTM EPS Tel Aviv, Israelâ March 5, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced successful treatment of the first patient in India with CGuard⢠EPS. The case was performed at Shri… Read More
InspireMD Announces Expansion of its Distribution Network
Tel Aviv, Israelâ March 1, 2018 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an exclusive distribution agreement with T-Vascular IKE Medical Supplies, in Greece, and Endo-Serv, SRL in the Caribbean, both of whom are premier suppliers of high-tech medical devices… Read More